01.11.11
PPD, Inc. has established a joint venture with Taijitu Biologics Ltd. (TBL), named BioDuro Biologics, to discover novel biotherapeutics. BioDuro Biologics aims to develop and commercialize an innovative technology platform for the discovery of first- and best-in-class monoclonal antibody therapies in collaboration with MAB Discovery GmbH in Munich, Germany. The JV will then provide drug discovery services based on this technology platform to global biopharma companies.
Based in Singapore, BioDuro Biologics allows PPD to take advantage of the growth and success of biotherapeutics and creates opportunities for BioDuro, PPD’s drug discovery business, to provide additional services for antibodies discovered using the new technology platform. PPD owns a majority stake in the JV and has committed to invest $25 million.
“Developing a best-in-class, innovative technology platform for the discovery of monoclonal antibodies allows us to continue to deliver highly valued discovery services for our clients in the growing area of large molecule drug discovery,” said Lee Babiss, Ph.D., executive vice president of global laboratory services for PPD. “As PPD continues to invest in drug discovery, we are well-positioned to deliver high quality, innovative drug discovery technologies and expertise that advance our clients’ compounds more quickly and cost efficiently.”
Stephan Fischer, Ph.D., founder and co-owner of TBL and MAB Discovery GmbH, will serve as a member of BioDuro Biologics’ board of directors and will lead the development of the technology platform, which is expected to be completed by mid-2011.
Based in Singapore, BioDuro Biologics allows PPD to take advantage of the growth and success of biotherapeutics and creates opportunities for BioDuro, PPD’s drug discovery business, to provide additional services for antibodies discovered using the new technology platform. PPD owns a majority stake in the JV and has committed to invest $25 million.
“Developing a best-in-class, innovative technology platform for the discovery of monoclonal antibodies allows us to continue to deliver highly valued discovery services for our clients in the growing area of large molecule drug discovery,” said Lee Babiss, Ph.D., executive vice president of global laboratory services for PPD. “As PPD continues to invest in drug discovery, we are well-positioned to deliver high quality, innovative drug discovery technologies and expertise that advance our clients’ compounds more quickly and cost efficiently.”
Stephan Fischer, Ph.D., founder and co-owner of TBL and MAB Discovery GmbH, will serve as a member of BioDuro Biologics’ board of directors and will lead the development of the technology platform, which is expected to be completed by mid-2011.